Skip to main content

Table 1 Patient clinical and pathological characteristics

From: Longitudinal autoantibody responses against tumor-associated antigens decrease in breast cancer patients according to treatment modality

Patients with Breast Cancer N = 200
 Age: Mean (SD) 58.9 (11.4)
 White Race: n (%) 193 (97%)
 BMI [kg/m2]: Mean (SD) 29.7 (6.6)
Smoking Status: n (%)
 Current 22 (11%)
 Never 120 (60%)
 Past 58 (29%)
 Family History Yes: n (%) 114 (58%)
Tumor Type: n (%)
 Invasive 148 (74%)
 in situ 52 (26%)
Tumor Max Dimension [cm]: n (%)
  ≤ 1 66 (36%)
  > 1 to ≤2 65 (35%)
  > 2 53 (29%)
Histology: n (%)
 Ductal and Lobular 3 (2%)
 Ductal 173 (87%)
 Lobular 21 (11%)
 Other 2 (1%)
 ER Positive: n (%) 171 (86%)
 PR Positive: n (%) 147 (74%)
HER2 Amplification: n (%)
 Negative 132 (66%)
 Positive 15 (8%)
 Unknown 53 (27%)
 Triple Negative: n (%) 18 (12%)
 Lymph Node Involvement: n (%) 47 (24%)
Matched Healthy Controls N = 200
 Age: Mean (SD) 58.8 (11.3)
 White Race: n (%) 192 (97%)
 BMI [kg/m2]: Mean (SD) 27.1 (5.5)
Smoking Status: n (%)
 Current 7 (4%)
 Never 125 (63%)
 Past 67 (34%)